Gross profit margins increased from 72.67% to 72.92% during the first time interval (12 months ending 2010-12-31 vs. 12 months ending 2009-12-31). For the second time interval, gross margins increased from 72.92% to 73.65% (12 months ending 2011-12-31 vs. 12 months ending 2010-12-31). And for the final time interval, gross margins increased from 73.65% to 73.84% (12 months ending 2012-12-31 vs. 12 months ending 2011-12-31).
The company's rheumatoid arthritis treatment, ORENCIA, posted double-digit gains in the most recent quarter, helping to drive up net sales.
( List compiled by Mary-Lynn Cesar, a Kapitall Writer. Gross margin data sourced from Google Finance. Quarterly sales data sourced from Zacks Investment Research. All other data sourced from Finviz.)